openPR Logo
Press release

Investigation for NASDAQ: GMDA Investors announced over possible Wrongdoing at Gamida Cell Ltd.

01-22-2022 04:20 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Gamida Cell Ltd. (NASDAQ: GMDA) shares over potential wrongdoing at Gamida Cell Ltd. wa

An investigation on behalf of investors in Gamida Cell Ltd. (NASDAQ: GMDA) shares over potential wrongdoing at Gamida Cell Ltd. wa

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Gamida Cell Ltd. .

Investors who purchased shares of Gamida Cell Ltd. (NASDAQ: GMDA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Gamida Cell Ltd. directors breached their fiduciary duties and caused damage to the company and its shareholders.

Isreal based Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases.

On November 11, 2021, Gamida Cell Ltd provided an update on the Company's Pre-Biologics License Application ("BLA") meeting with the U.S. Food and Drug Administration for omidubicel, the Company's proposed blood cancer treatment. Specifically, Gamida Cell Ltd disclosed that "[t]he FDA requested that Gamida Cell provide revised analysis of the manufacturing data generated at Gamida Cell's wholly-owned commercial manufacturing facility to demonstrate the comparability to the omidubicel that was produced at the clinical manufacturing sites for the Phase 3 study," a development that the Company acknowledged would bring a "delay in timing to bring omidubicel to patients after a potential FDA approval[.]"

Shares of Gamida Cell Ltd. (NASDAQ: GMDA) declined from $4.56 per share on November 1, 2021, to as low as $2.25 per share on December 6, 2021.

Those who purchased shares of Gamida Cell Ltd. (NASDAQ: GMDA) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for NASDAQ: GMDA Investors announced over possible Wrongdoing at Gamida Cell Ltd. here

News-ID: 2535410 • Views: 407

More Releases from Shareholders Foundation

DocuSign, Inc. (NASDAQ: DOCU) Long Term Investor Notice: Lawsuit against Directo …
A current long-term investor in shares of DocuSign, Inc. (NASDAQ: DOCU) filed a lawsuit against certain directors of DocuSign, Inc over alleged breaches of fiduciary duties. Investors who are current long term investors in DocuSign, Inc. (NASDAQ: DOCU) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The plaintiff alleges that the CEO and certain directors of DocuSign, Inc mislead investors with predictions
Investigation for Long-Term Investors in Telos Corporation (NASDAQ: TLS) over po …
An investigation was announced for current long-term investors in shares of Telos Corporation (NASDAQ: TLS) concerning potential breaches of fiduciary duties by certain directors ofTelos Corporation. Investors who are current long term investors in Telos Corporation (NASDAQ: TLS) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: TLS stocks
Investigation announced for Investors in Carvana Co. (NYSE: CVNA) over possible …
An investigation was announced over potential securities laws violations by Carvana Co. in connection with certain financial statements. Investors who purchased shares of Carvana Co. (NYSE: CVNA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Carvana Co. (NYSE: CVNA) concerning whether a series of statements
Investigation announced for Investors in New Oriental Education & Technology Gro …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of New Oriental Education & Technology Group Inc.. Investors who are current long term investors in New Oriental Education & Technology Group Inc. (NYSE: EDU) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE:

All 5 Releases


More Releases for Gamida

Stem Cell Therapy Market Growth Trends by Top Key Players Vcanbio, Gamida Cell, …
Stem Cell Therapy market researchers are making efforts to discover novel methods to create human stem cells. This will increase the demand as well as supply for stem cell production and potential investigation in disease management. Increasing investment & research grants for developing safe and effective stem cell therapy products, the growing patient base for target diseases, concentrated product pipelines, increasing approval of the new clinical trials, rapid technological advancement
Stem Cell Therapy Market Impressive Gains including key players Vcanbio, Gamida …
A new business intelligence report released by HTF MI with title “Global Stem Cell Therapy Market Size, Status and Forecast 2025” that targets and provides comprehensive market analysis with future prospects to 2023. The analysts of the study have garnered extensive research methodologies and data sources (i.e Secondary & Primary Sources) in order to generate collective and useful information that delivers latest market undercurrents and industry trends. Request Sample Report
Global Thalassemia Market Size, Status and Forecast 2025 : Bluebird bio, Inc., G …
Qyresearchreports include new market research report "Global Thalassemia Market Size, Status and Forecast 2025" to its huge collection of research reports. The global market for Thalassemia has been seen on a few perspectives that are for all intents and purposes there, and have fixed up the market circumstance to the epic degree. The report additionally displays unmistakable experience and information related to global Thalassemia market. The key purpose behind the report
Jan 11, 2018: Vascular Prostheses Market Forecast 2023 Labcor, Vascutek, Cryolif …
Vascular Prostheses Market Research 2018 A market study "Global Vascular Prostheses Market" examines the performance of the Vascular Prostheses market 2018. It encloses an in-depth Research of the Vascular Prostheses market state and the competitive landscape globally. This report analyzes the potential of Vascular Prostheses market in the present and the future prospects from various angles in detail. The Global Vascular Prostheses Market 2018 report includes Vascular Prostheses market Revenue, market Share,
Hemoglobinopathies Drugs Market Reports 2017-Gamida Cell, Alnylam Pharmaceutical …
Apex Market Reports, recently published a detailed market research study focused on the "Hemoglobinopathies Drugs Market" across the global, regional and country level. The report provides 360° analysis of "Hemoglobinopathies Drugs Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Hemoglobinopathies Drugs industry, and estimates the future trend of Hemoglobinopathies Drugs market
Global Regenerative Medicine Market 2017 : Vcanbio, Gamida Cell, Golden Meditech …
QY Market Research published, Top Manufacturers Analysis Of Regenerative Medicine Research Report. A market study based on the "Regenerative Medicine Market" across the globe, recently added to the repository of Market Research, is titled ‘Global Regenerative Medicine Market 2017’. The research report analyses the historical as well as present performance of the worldwide Regenerative Medicine industry, and makes predictions on the future status of Regenerative Medicine market on the basis